The ZUSDURI launch trajectory (73% QoQ growth, 45% repeat prescribers) is the primary catalyst, monitor weekly prescription data and upcoming KOL events for continued acceleration. The EPS miss is minor and likely overshadowed by the revenue beat and patent news. Watch for UGN-103 NDA submission in Q3 2026 as the next major pipeline catalyst.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 5 $46.43entry
- T+1 · 3mo ago −1.79%α −1.63% · $45.60
- T+5 · 3mo ago +5.54%α +5.18% · $49.00
- T+20 · 3mo ago −4.33%α −3.73% · $44.42
- T+60 · 19d ago −27.89%α −27.84% · $33.48
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
UroGen reported Q2 2026 revenue of $72.5M (consensus $63.5M, +14.2% beat), driven by ZUSDURI's $50.4M in revenue (73% QoQ growth). EPS of -$0.28 was a 5.7% miss vs consensus -$0.27. The company raised FY2026 operating expense guidance to $260M-$270M to accelerate ZUSDURI commercialization and pipeline investment. ZUSDURI's accelerating launch trajectory and a new patent allowance extending protection to 2044 are strong positives, but the EPS miss and rising spend temper the outlook.
Key Financial Metrics
Key Facts
- Total revenue $72.5M in Q2 2026, up 199% YoY from $24.2M
- ZUSDURI revenue $50.4M, 73% QoQ growth from Q1 2026
- EPS -$0.28 vs consensus -$0.27 (5.7% miss)
- FY2026 operating expense guidance raised to $260M-$270M from $240M-$250M
- New U.S. patent allowance expected to protect ZUSDURI and UGN-103 into July 2044
- UGN-103 NDA submission on track for Q3 2026; UGN-501 Phase 1 trial expected Q4 2026
- Net loss narrowed to $14.4M from $49.9M in Q2 2025
- Cash and marketable securities $108.0M as of June 30, 2026
Financial Impact
Revenue beat consensus by $9.0M (+14.2%); EPS missed by $0.01 (-5.7%); operating expense guidance raised by $20M at midpoint
Risk Factors
- EPS miss vs consensus despite strong revenue beat
- Rising operating expenses ($260M-$270M guidance) may pressure cash runway
- JELMYTO revenue declined 9% YoY to $22.0M
- Teva settlement allows generic JELMYTO entry on September 15, 2030
- Cash burn: $108.0M at June 30 vs $120.5M at Dec 31, 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-025793 |
| Document: urgn20260730_8k.htm | 0001437749-26-025793 |
| Document: 0001437749-26-025793-index-headers.html | 0001437749-26-025793 |
| Document: 0001437749-26-025793-index.html | 0001437749-26-025793 |
| Document: 0001437749-26-025793.txt | 0001437749-26-025793 |
| 8-K Data (Synthetic) | 0001437749-26-025793 |
Track record
16 reports on URGN
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +54.89% at T+60 after the Mar 2, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $25.90 Now $28.10 +8.49% settles Nov 23
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bearish 6/10 Entry $28.74 to $26.10 Now $28.10 +2.23% ▲ +9.19% +8.27% vs SPY
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $34.36 to $26.31 Now $28.10 −18.22% ▼ −23.43% −23.51% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $33.75 to $28.74 Now $28.10 −16.74% ▼ −14.84% −14.13% vs SPY
- Oct 19, 202628d ago Press Release Bullish 6/10 Entry $34.15 to $34.23 Now $28.10 −17.72% ▲ +0.23% +0.38% vs SPY
- Oct 9, 20265w ago 144 Neutral 2/10 Entry $36.83 to $34.56 Now $28.10 −23.70% ▼ −6.16% −4.20% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $45.00 to $43.04 Now $28.10 −37.56% ▼ −4.36% −4.02% vs SPY
- Aug 20, 202612w ago 8-K Neutral 4/10 Entry $46.80 to $45.50 Now $28.10 −39.96% ▼ −2.78% −3.89% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 Viewing Entry $46.43 to $49.00 Now $28.10 −39.48% ▲ +5.54% +5.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers